High Tide Closes Acquisition of a Majority Stake in Remexian Pharma GmbH
1. HITI completed a 51% acquisition of Remexian for €26.4 million. 2. The acquisition marks HITI's entry into Europe's regulated cannabis market. 3. HITI aims for long-term growth and global leadership with this deal. 4. Transaction includes options for acquiring remaining 49% stake in Remexian. 5. HITI expands its revenue base beyond Canada with the Remexian acquisition.